Contraception use in women with hypertension

Jennifer Corbelli, Eleanor Schwarz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hypertension is among the most common conditions that affect women of reproductive age. It is also a common complication of pregnancy, and should be treated in pregnant women with blood pressures =160/110. For blood pressures 140-159/90-109, no clear data exist to demonstrate benefits of treatment. When treatment is indicated, labetalol and methyldopa are first-line agents. Most women, with or without hypertension, will not have an adverse effect on blood pressure from any form of contraception. Progestin-only methods, including the pill, injection, subdermal implant, and intrauterine device, are safe in women with hypertension, even if blood pressure is poorly controlled. Estrogen-containing methods, including the pill, patch, and ring, have all been shown to increase blood pressure, although the degree of increase has not been well established in the literature. In women with hypertension using these methods, data show an increased risk of both stroke and myocardial infarction, compared to women without hypertension. For these reasons, all women should have their blood pressure measured prior to initiation of estrogen-containing contraceptives. These methods are graded as category 4 (method poses an unacceptable health risk) in women with blood pressures ≥160/100. Because of data demonstrating a dose-dependent risk of cardiovascular events in women using contraceptives containing estrogen, when these methods are selected, doses ≤35 μg are universally preferred.

Original languageEnglish (US)
Title of host publicationContraception for the Medically Challenging Patient
PublisherSpringer New York
Pages41-53
Number of pages13
ISBN (Electronic)9781493912339
ISBN (Print)9781493912322
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Contraception
Hypertension
Blood Pressure
Estrogens
Contraceptive Agents
Labetalol
Methyldopa
Intrauterine Devices
Pregnancy Complications
Progestins
Pregnant Women
Stroke
Myocardial Infarction
Injections
Health
Therapeutics

ASJC Scopus subject areas

  • Health Professions(all)
  • Medicine(all)

Cite this

Corbelli, J., & Schwarz, E. (2014). Contraception use in women with hypertension. In Contraception for the Medically Challenging Patient (pp. 41-53). Springer New York. https://doi.org/10.1007/978-1-4939-1233-9_3

Contraception use in women with hypertension. / Corbelli, Jennifer; Schwarz, Eleanor.

Contraception for the Medically Challenging Patient. Springer New York, 2014. p. 41-53.

Research output: Chapter in Book/Report/Conference proceedingChapter

Corbelli, J & Schwarz, E 2014, Contraception use in women with hypertension. in Contraception for the Medically Challenging Patient. Springer New York, pp. 41-53. https://doi.org/10.1007/978-1-4939-1233-9_3
Corbelli J, Schwarz E. Contraception use in women with hypertension. In Contraception for the Medically Challenging Patient. Springer New York. 2014. p. 41-53 https://doi.org/10.1007/978-1-4939-1233-9_3
Corbelli, Jennifer ; Schwarz, Eleanor. / Contraception use in women with hypertension. Contraception for the Medically Challenging Patient. Springer New York, 2014. pp. 41-53
@inbook{12170515201d42aa9010e40a3c722975,
title = "Contraception use in women with hypertension",
abstract = "Hypertension is among the most common conditions that affect women of reproductive age. It is also a common complication of pregnancy, and should be treated in pregnant women with blood pressures =160/110. For blood pressures 140-159/90-109, no clear data exist to demonstrate benefits of treatment. When treatment is indicated, labetalol and methyldopa are first-line agents. Most women, with or without hypertension, will not have an adverse effect on blood pressure from any form of contraception. Progestin-only methods, including the pill, injection, subdermal implant, and intrauterine device, are safe in women with hypertension, even if blood pressure is poorly controlled. Estrogen-containing methods, including the pill, patch, and ring, have all been shown to increase blood pressure, although the degree of increase has not been well established in the literature. In women with hypertension using these methods, data show an increased risk of both stroke and myocardial infarction, compared to women without hypertension. For these reasons, all women should have their blood pressure measured prior to initiation of estrogen-containing contraceptives. These methods are graded as category 4 (method poses an unacceptable health risk) in women with blood pressures ≥160/100. Because of data demonstrating a dose-dependent risk of cardiovascular events in women using contraceptives containing estrogen, when these methods are selected, doses ≤35 μg are universally preferred.",
author = "Jennifer Corbelli and Eleanor Schwarz",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1233-9_3",
language = "English (US)",
isbn = "9781493912322",
pages = "41--53",
booktitle = "Contraception for the Medically Challenging Patient",
publisher = "Springer New York",

}

TY - CHAP

T1 - Contraception use in women with hypertension

AU - Corbelli, Jennifer

AU - Schwarz, Eleanor

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hypertension is among the most common conditions that affect women of reproductive age. It is also a common complication of pregnancy, and should be treated in pregnant women with blood pressures =160/110. For blood pressures 140-159/90-109, no clear data exist to demonstrate benefits of treatment. When treatment is indicated, labetalol and methyldopa are first-line agents. Most women, with or without hypertension, will not have an adverse effect on blood pressure from any form of contraception. Progestin-only methods, including the pill, injection, subdermal implant, and intrauterine device, are safe in women with hypertension, even if blood pressure is poorly controlled. Estrogen-containing methods, including the pill, patch, and ring, have all been shown to increase blood pressure, although the degree of increase has not been well established in the literature. In women with hypertension using these methods, data show an increased risk of both stroke and myocardial infarction, compared to women without hypertension. For these reasons, all women should have their blood pressure measured prior to initiation of estrogen-containing contraceptives. These methods are graded as category 4 (method poses an unacceptable health risk) in women with blood pressures ≥160/100. Because of data demonstrating a dose-dependent risk of cardiovascular events in women using contraceptives containing estrogen, when these methods are selected, doses ≤35 μg are universally preferred.

AB - Hypertension is among the most common conditions that affect women of reproductive age. It is also a common complication of pregnancy, and should be treated in pregnant women with blood pressures =160/110. For blood pressures 140-159/90-109, no clear data exist to demonstrate benefits of treatment. When treatment is indicated, labetalol and methyldopa are first-line agents. Most women, with or without hypertension, will not have an adverse effect on blood pressure from any form of contraception. Progestin-only methods, including the pill, injection, subdermal implant, and intrauterine device, are safe in women with hypertension, even if blood pressure is poorly controlled. Estrogen-containing methods, including the pill, patch, and ring, have all been shown to increase blood pressure, although the degree of increase has not been well established in the literature. In women with hypertension using these methods, data show an increased risk of both stroke and myocardial infarction, compared to women without hypertension. For these reasons, all women should have their blood pressure measured prior to initiation of estrogen-containing contraceptives. These methods are graded as category 4 (method poses an unacceptable health risk) in women with blood pressures ≥160/100. Because of data demonstrating a dose-dependent risk of cardiovascular events in women using contraceptives containing estrogen, when these methods are selected, doses ≤35 μg are universally preferred.

UR - http://www.scopus.com/inward/record.url?scp=84956805958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956805958&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1233-9_3

DO - 10.1007/978-1-4939-1233-9_3

M3 - Chapter

SN - 9781493912322

SP - 41

EP - 53

BT - Contraception for the Medically Challenging Patient

PB - Springer New York

ER -